| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 4.06 Billion |
| Market Size (2030) | USD 5.37 Billion |
| CAGR (2025 - 2030) | 5.71 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Molecular Diagnostics For Emerging Infectious Diseases Market Analysis
The Molecular Diagnostics For Emerging Infectious Diseases Market size is estimated at USD 4.06 billion in 2025, and is expected to reach USD 5.37 billion by 2030, at a CAGR of 5.71% during the forecast period (2025-2030).
The market growth of molecular diagnostics for emerging infectious diseases is driven by various factors, such as the increasing incidence of infectious diseases, technological advancements in molecular diagnostics, and growing awareness and health initiatives.
The increase in infectious diseases, including chikungunya virus infection, avian influenza and others, has escalated the need for rapid and precise diagnostic solutions, thus fueling the market growth of molecular diagnostics. For instance, the data published by the European Centre for Disease Prevention and Control in October 2024, reported that around 460 thousand cases of chikungunya virus disease (CHIKVD) have been reported globally across 23 countries, including 15 in the Americas, 6 in Asia, 1 in Africa, and 1 in Europe in 2024. Additionally, the data published by the European Centre for Disease Prevention and Control in January 2024 mentioned that there had been 883 reported human cases of avian influenza A(H5N1) globally in 23 countries, such as Spain, the United States, the United Kingdom, and others. Thus, the rising emerging infectious diseases across the world are anticipated to boost the demand for advanced molecular diagnostics technologies, driving market growth.
Moreover, technological advancements in molecular diagnostics, including Polymerase Chain Reaction (PCR), next-generation sequencing (NGS), and CRISPR-based assays, improve the sensitivity, specificity, and detection speed. For instance, in August 2024, Seegene Inc. introduced the development of its PCR test assays in response to the public health emergency of international concern (PHEIC) declared by the World Health Organization (WHO) due to the global spread of mpox. The Novaplex HSV-1&2/VZV/MPXV Assay (RUO) was designed to identify four viruses, including the mpox virus and other significant STI-causing pathogens, provides reliable results. Additionally, in June 2024, Roche received approval from the United States Food and Drug Administration (FDA) for emergency use authorization (EUA) for its cobas liat SARS-CoV-2, Influenza A/B, and respiratory syncytial virus (RSV) nucleic acid test. This automated, multiplex, real-time polymerase chain reaction (RT-PCR) assay, designed for the cobas liat system, delivers results in just 20 minutes. Thus, such advancements in molecular diagnostics are anticipated to boost its adoption and drive market growth over the forecast period.
Hence, the increasing prevalence of emerging infectious diseases such as chikungunya virus infection, avian influenza, and others, as well as technological advancements in molecular diagnostics technologies, are significant factors driving the market growth. However, the high cost of advanced molecular diagnostic technologies and regulatory challenges may affect the market growth of molecular diagnostics for emerging infectious diseases over the forecast period.
Molecular Diagnostics For Emerging Infectious Diseases Market Trends
The Reagents and Kits Segment is Expected to Hold a Significant Market Share in Molecular Diagnostics for Emerging Infectious Diseases Market Over the Forecast Period
Molecular diagnostic reagents and kits are tools designed to examine biological samples at the molecular scale to identify specific nucleic acids (DNA or RNA), proteins, or other infectious disease-related biomarkers and are essential for delivering rapid, precise, and sensitive diagnostic outcomes. Thus, due to their advantages, molecular diagnostic reagents and kits are likely to be adopted and drive the segment's growth.
The increasing product launches are likely to boost product availability and, hence, drive segment growth. For instance, in August 2024, a homegrown RT-PCR testing kit was developed in India to fight against Monkeypox, which has received approval from the Central Drugs Standard Control Organisation (CDSCO). The IMDX Monkeypox Detection RT-PCR Assay, manufactured by Siemens Healthineers, marks a major milestone in the country’s "Make in India" initiative and is essential for tackling the Monkeypox public health emergency. Thus, the rising product developments are expected to drive the segment growth.
Significant initiatives taken by the market players to enhance product availability in countries are anticipated to drive the segment growth. For instance, in September 2024, QIAGEN and Bio-Manguinhos/Fiocruz collaborated to improve the detection of dengue in Brazil's national screening initiatives, and as part of this partnership, QIAGEN’s solutions will be integrated into the screening kits and marketed under the Bio-Manguinhos brand. Bio-Manguinhos/Fiocruz's ZCD-typing kit is now capable of identifying and distinguishing samples of Zika, chikungunya, and dengue while also allowing for the typing of dengue, which aids in the country's epidemiological surveillance efforts. Additionally, in May 2024, En Carta Diagnostics secured USD 1.63 million in pre-seed funding, which will allow the company to significantly advance its efforts to gather preclinical data on a prototype diagnostic kit for Lyme disease while also enhancing its capacity for industrial scaling. The funds will be utilized to create a diagnostic kit designed for the rapid, autonomous detection of Lyme disease within minutes. Thus, such initiatives taken by the market players, such as collaborations, are anticipated to contribute to the segment growth.
Therefore, owing to the above-mentioned factors, such as rising investments, collaboration, and product developments, advancements in molecular diagnostic reagents and kits are expected to boost the segment's growth.
Understand The Key Trends Shaping This Market
Download PDF
North America is Anticipated to Hold the Largest Share in the Molecular Diagnostics for Emerging Infectious Diseases Market Over the Forecast Period
The North American molecular diagnostics for emerging infectious diseases market is expected to hold a significant share during the forecast period owing to factors such as the high burden of infectious diseases, technological advancements in molecular diagnostics, rising government funding, and other market player initiatives such as new product developments.
The significant burden of infections, such as avian influenza, is fueling the demand for molecular diagnostics to provide quick and precise detection, making them essential for controlling outbreaks, leading to an increase in the demands of molecular diagnostics, thereby driving the market growth. For instance, according to the data updated by the United States Centers for Disease Control and Prevention, reported that there have been 20 reported cases of avian influenza A(H5) virus infection in humans in the United States in April 2024. Of these cases, 10 were linked to contact with poultry infected with the H5N1 bird flu, while 9 were connected to sick or infected dairy cows. Additionally, an article published in the Environmental Health Perspectives Journal in February 2024 reported that the estimated annual cases of Lyme disease in Canada are anticipated to range from 120 thousand to over 500 thousand by 2050. Thus, the rising burden of emerging infectious disease is anticipated to fuel the demands for rapid and accurate molecular diagnostic tools and thus contributing to the market growth of molecular diagnostics for emerging infectious diseases over the forecast period.
Significant initiatives taken by the market players are expected to boost technological advancements and drive the market growth of molecular diagnostics for emerging infectious diseases over the forecast period. For instance, in July 2024, Co-Diagnostics, Inc. expanded its vector control technology across the 15 states of the United States. This technology enabling the mosquito abatement districts (MADs) and other vector control clients to leverage Vector smart PCR tests, which are utilized for environmental (non-diagnostic) surveillance of mosquito populations regarding mosquito-borne diseases such as West Nile virus, Zika, dengue, and chikungunya and obtain same-day results, thereby facilitating faster and more effective disease transmission prevention for humans. Additionally, in May 2023, Hologic Inc. received 510(k) clearance from the United States Food and Drug Administration (FDA) for its molecular diagnostic assay Panther Fusion SARS-CoV-2/Flu A/B/RSV assay which can identify and distinguish between 4 of the most common respiratory viruses that can show similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B), and respiratory syncytial virus (RSV). Thus, such initiatives taken by the market players are expected to fuel the market growth in the region.
Therefore, owing to the above-mentioned factors, such as the increasing infectious disease burden and key market player initiatives, the market growth of molecular diagnostics for emerging infectious diseases in the North American region will be boosted over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Molecular Diagnostics For Emerging Infectious Diseases Industry Overview
The molecular diagnostics for emerging infectious diseases market is fragmented and comprises of numerous key market players. Companies engage in various initiatives and strategies to enhance the development and production of molecular diagnostic products and technologies worldwide. Significant market players in this market include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd , Abbott Laboratories, Illumina, Inc., BioMerieux, among others.
Molecular Diagnostics For Emerging Infectious Diseases Market Leaders
-
Thermo Fisher Scientific, Inc.
-
F. Hoffmann-La Roche Ltd
-
Abbott Laboratories
-
Illumina Inc.
-
BioMerieux
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Molecular Diagnostics For Emerging Infectious Diseases Market News
- July 2024: OnsiteGene Inc. launched a real-time polymerase chain reaction (PCR) instrument XDive PCR instrument in the United States that operates in just 5 minutes, delivering enhanced efficiency and sensitivity, and is approved for testing COVID-19 and Monkeypox.
- June 2024: QIAGEN released 35 new wet-lab validated digital PCR microbial DNA detection assays for its QIAcuity digital PCR (dPCR) platform, marking a significant enhancement to its microbial research capabilities. This expansion includes assays targeting key pathogens, such as dengue virus serotypes 1 to 4, monkeypox clades I and II, and chikungunya, along with other pathogens.
Molecular Diagnostics For Emerging Infectious Diseases Industry Segmentation
According to the scope, emerging infectious diseases (EIDs) are diseases caused by newly discovered pathogens or those that have notably risen in frequency or expanded their geographical distribution, such as COVID-19, antimicrobial resistant tuberculosis and malaria, among others. Molecular diagnostics for emerging infectious diseases utilize advanced technologies to detect, identify, and monitor pathogens at the molecular level, focusing on specific DNA or RNA sequences, such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and more, that are associated with various diseases.
The molecular diagnostics for emerging infectious diseases market is segmented by product type, technology, application, end-user and geography. By product type, the market is segmented into instruments, reagents and kits and other product types. By technology, the market is segmented into in-situ hybridization, chips and microarrays, mass spectrometry, sequencing, polymerase chain reaction (PCR), and other technologies. By application, the market is segmented into pathogen detection, antimicrobial resistance testing, syndromic testing and other applications. By end-user, the market is segmented into hospitals and clinics, diagnostics laboratories, research institutes and other end-user. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
| By Product Type | Instruments | ||
| Reagents and Kits | |||
| Other Product Types | |||
| By Technology | In-Situ Hybridization | ||
| Chips and Microarrays | |||
| Mass Spectrometry | |||
| Sequencing | |||
| Polymerase Chain Reaction (PCR) | |||
| Other Technologies | |||
| By Application | Pathogen Detection | ||
| Antimicrobial Resistance Testing | |||
| Syndromic Testing | |||
| Other Applications | |||
| By End-User | Hospitals and Clinics | ||
| Diagnostics Laboratories | |||
| Other End-Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Molecular Diagnostics For Emerging Infectious Diseases Market Research FAQs
How big is the Molecular Diagnostics For Emerging Infectious Diseases Market?
The Molecular Diagnostics For Emerging Infectious Diseases Market size is expected to reach USD 4.06 billion in 2025 and grow at a CAGR of 5.71% to reach USD 5.37 billion by 2030.
What is the current Molecular Diagnostics For Emerging Infectious Diseases Market size?
In 2025, the Molecular Diagnostics For Emerging Infectious Diseases Market size is expected to reach USD 4.06 billion.
Who are the key players in Molecular Diagnostics For Emerging Infectious Diseases Market?
Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Abbott Laboratories, Illumina Inc. and BioMerieux are the major companies operating in the Molecular Diagnostics For Emerging Infectious Diseases Market.
Which is the fastest growing region in Molecular Diagnostics For Emerging Infectious Diseases Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Molecular Diagnostics For Emerging Infectious Diseases Market?
In 2025, the North America accounts for the largest market share in Molecular Diagnostics For Emerging Infectious Diseases Market.
What years does this Molecular Diagnostics For Emerging Infectious Diseases Market cover, and what was the market size in 2024?
In 2024, the Molecular Diagnostics For Emerging Infectious Diseases Market size was estimated at USD 3.83 billion. The report covers the Molecular Diagnostics For Emerging Infectious Diseases Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Molecular Diagnostics For Emerging Infectious Diseases Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
